Predictors of response to tofacitinib or etanercept in a Phase 3 randomised, non-inferiority study in patients with moderate to severe chronic plaque psoriasis

被引：0
|
作者：
Lambert, J. [1 ]
Strohal, R. [2 ]
de la Cruz, C. [3 ]
Thaci, D. [4 ]
Bachelez, H. [5 ]
Iversen, L. [6 ]
Rottinghaus, S. [7 ]
Tallman, A. [8 ]
Tan, H. [7 ]
Berstein, G. [9 ]
机构：
[1] Ghent Univ Hosp, Ghent, Belgium
[2] Fed Acad Teaching Hosp Feldkirch, Feldkirch, Austria
[3] Clin Dermacross, Santiago, Chile
[4] Univ Med Sch, Comprehens Ctr Inflammat Med, Schleswig Holstein Campus, Lubeck, Germany
[5] Univ Paris Diderot, Hop St Louis, APHP, Sorbonne Paris Cite, Paris, France
[6] Aarhus Univ Hosp, Aarhus C, Denmark
[7] Pfizer Inc, Groton, CT 06340 USA
[8] Pfizer Inc, New York, NY USA
[9] Pfizer Inc, Cambridge, MA USA
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷
关键词：
etanercept; psoriasis; tofacitinib;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P152
引用
收藏
页码：78 / 78
页数：1
相关论文
共 50 条
  • [21] Etanercept in patients with moderate to severe plaque psoriasis: a retrospective case cohort analysis
    Perera, G.
    Fonia, A.
    Smith, C.
    Barker, J. N. W. N.
    BRITISH JOURNAL OF DERMATOLOGY, 2009, 161 : 26 - 27
  • [22] Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis
    Langley, Richard G.
    Kasichayanula, Sree
    Trivedi, Mona
    Aras, Girish A.
    Kaliyaperumal, Arunan
    Yuraszeck, Theresa
    Gibbs, John
    Gibbs, Megan
    Kricorian, Greg
    Paller, Amy S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (03): : 340 - 346
  • [23] Baseline characteristics of patients with moderate to severe plaque psoriasis: post-hoc analysis of response to etanercept
    Gisondi, Paolo
    Girolomoni, Giampiero
    de Vlam, Kurt
    Al Hammadi, Anwar
    Carneiro, Sueli
    Arenberger, Petr
    Gallo, Gaia
    Jones, Heather
    Hsu, Ming-Ann
    Ferdousi, Tahmina
    Szumski, Annette
    Chhabra, Amit
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S26 - S26
  • [24] Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis
    Griffiths, C. E. M.
    Vender, R.
    Sofen, H.
    Kircik, L.
    Tan, H.
    Rottinghaus, S. T.
    Bachinsky, M.
    Mallbris, L.
    Mamolo, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (02) : 323 - 332
  • [25] A phase III, multicenter, randomized study comparing ustekinumab and etanercept for the treatment of moderate to severe plaque psoriasis
    Griffiths, C.
    Menter, A.
    Strober, B.
    Fidelus-Gort, R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : AB166 - AB166
  • [26] Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial
    Abe, Masatoshi
    Nishigori, Chikako
    Torii, Hideshi
    Ihn, Hironobu
    Ito, Kei
    Nagaoka, Makoto
    Isogawa, Naoki
    Kawaguchi, Isao
    Tomochika, Yukiko
    Kobayashi, Mihoko
    Tallman, Anna M.
    Papp, Kim A.
    JOURNAL OF DERMATOLOGY, 2017, 44 (11): : 1228 - 1237
  • [27] Early clinical response as a predictor of efficacy in moderate to severe psoriasis patients treated with tofacitinib in a phase 2 study
    Gordon, Kenneth
    Strober, Bruce
    Tan, Huaming
    Yang, Lingfeng
    Wolk, Robert
    Mallbris, Lotus
    Valdez, Hernan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB231 - AB231
  • [28] Efficacy and safety results of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
    Menter, A.
    Gottlieb, A.
    Leonardi, C.
    Kerdel, F.
    Gu, Y.
    Valdes, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 : 38 - 39
  • [29] Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis
    Leonardi, C
    Goffe, B
    Sobell, J
    Caro, I
    Wang, X
    Papp, K
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A58 - A58
  • [30] Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis
    Papp, KA
    Miller, B
    Gordon, KB
    Caro, I
    Kwon, P
    Compton, PG
    Leonardi, CL
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (04) : S164 - S170
12345